Overview

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, crossover study to assess the bioequivalence of 1 risedronate 150 mg tablet versus 2 risedronate 75 mg tablets administered as a single oral dose. Approximately 320 subjects will be enrolled from 4 study centers in the U.S.
Phase:
Phase 1
Details
Lead Sponsor:
Warner Chilcott
Collaborator:
Sanofi
Treatments:
Etidronic Acid
Risedronate Sodium
Risedronic Acid